These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 21403611)

  • 21. The use of doxorubicine at low doses for elevation of LAK-activity toward explants and cells of MC-rhabdomyosarcoma and B16 melanoma resistant to doxorubicin.
    Berezhnaya NM; Vinnichuk YD; Belova OB
    Exp Oncol; 2008 Mar; 30(1):52-5. PubMed ID: 18438341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between tumor and immune system: the role of tumor cell biology.
    Berezhnaya NM
    Exp Oncol; 2010 Sep; 32(3):159-66. PubMed ID: 21403611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Accomplishments and perspectives in tumor diagnostics and treatment].
    Spuzić I
    Glas Srp Akad Nauka Med; 2002; (47):21-32. PubMed ID: 16078439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human natural killer cells: a comprehensive review.
    Sinkovics JG; Horvath JC
    Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
    Hamaï A; Benlalam H; Meslin F; Hasmim M; Carré T; Akalay I; Janji B; Berchem G; Noman MZ; Chouaib S
    Tissue Antigens; 2010 Jan; 75(1):1-8. PubMed ID: 20196816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An outsider's perspective--ecotaxis revisited: an integrative review of cancer environment, iron and immune system cells.
    de Sousa M
    Integr Biol (Camb); 2011 Apr; 3(4):343-9. PubMed ID: 21180734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of tumor stroma in the interaction between tumor and immune system.
    Blankenstein T
    Curr Opin Immunol; 2005 Apr; 17(2):180-6. PubMed ID: 15766679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene transfer approaches in cancer immunotherapy.
    Larin SS; Georgiev GP; Kiselev SL
    Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy.
    Bereznaya NM; Chekhun VF
    Exp Oncol; 2007 Mar; 29(1):2-12. PubMed ID: 17431381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.
    Görgün G; Anderson KC
    Immunotherapy; 2011 Oct; 3(10):1253-64. PubMed ID: 21995575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.